Skip to content
  • NON-INVASIVE PRENATAL TESTING (NIPT)
  • PREIMPLANTATION GENETIC SCREENING (PGS)
  • CANCER MOLECULAR DIAGNOSIS

NIGM is a form of Non-Invasive Prenatal Testing (NIPT) based on next-generation sequencing using cell-free DNA (cfDNA) in maternal blood to evaluate possible chromosomal conditions in pregnancy. It can be performed as early as 9 gestational weeks using a single tube of blood.

NIGM  offers the prenatal test with a focused and clinically relevant menu that screens for chromosomal aneuploidies, specific sex chromosome aneuploidies, and pathogenic microdeletions/duplications.

Simple
Test from a small 10ml maternal blood sample as early as 9 gestational weeks
Accurate

Proven >99% sensitivity based on a test of more than 20,000 pregnancies

Fast & Convenient
  • Quick test from sample preparation to report generation within 24 hours 
  • Simplified operation: Automated and localized data analysis and report
Flexible

Compatible with most standard NGS library prep kits and bioinformatics tools

artificial insemination

Preimplanation Genetic Testing for Aneuploidy (PGT-A), which is applied to identify chromosomal abnormalities and that represents the broadest indication to preimplantation genetics at present. Preimplantation genetic testing for aneuploidy identififies chromosomal abnormalities in embryo samples for the research of in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). These genetic insights may increase the probability of success for future pregnancies and healthier future generations.

Easy-to-use

Automated and simplified sequencing and data analysis workflow

Fast

Quick test from sample preparation to final report within 24 hours

Flexible

Compatible with common used NGS library preparation kits and bioinformatics tools

Sensitive

Accurately detect different types of chromosomal mutations even in a low copies

1684911162-3

Clinical diagnostic whole‐exome sequencing (WES) is a powerful tool for patients with undiagnosed genetic disorders. WES employs high-throughput sequencing of more than 20,000 genes per individual, enriched through sequence capture technology. WES targets all protein-coding regions (~1% of the whole genome) responsible for 85% of known disease-causing variants. It allows for molecular diagnosis of genetic diseases and enables the exploration of novel mutations and new pathogenic mechanisms. Compared to whole genome sequencing, WES has the advantage of a greater sequencing depth and delivers more effective data.For patients with symptoms of genetic disorders, clinical exome sequencing plays an important role in quickly identifying potential variants. Clinical exome sequencing offers a one-step solution for challenging issues, such as diagnosing patients with genetic heterogeneity or atypical presentation, where it is unclear which genes are causing the specific genetic condition. 

Easy-to-use

Automated and simplified sequencing and data analysis workflow

Fast

Quick test from sample preparation to final report within 2 weeks

GET A QUOTE